FDA struggles to remain independent amid race for virus cure

FDA struggles to remain independent amid race for virus cure

Baptism by fire

When Hahn, a cancer doctor by training, took office in December, the hottest issue facing the FDA was e-cigarettes. But within weeks, the coronavirus reached the United States, thrusting him into a starring role in the government’s pandemic response — despite his lack of prior experience in public health, infectious diseases or government.

The FDA began working around the clock to evaluate potential coronavirus tests, treatments and vaccines, even as the president promoted unproven drugs from the White House podium and promised a shot within the year.

Some of the current and former officials who spoke to POLITICO said they were troubled that Hahn hasn’t pushed back more forcefully on outside influences. His relative inexperience has exacerbated worries within the agency about whether it can remain independent of White House pressure to fast-track experimental coronavirus vaccines or quell lingering questions about the reliability of antibody testing, said three current and former health officials.

“I don’t know where his voice is in this,” a former HHS official said.

So far, Hahn “has not put his foot down on any issue,” said a current official. “Maybe some of that is the politicization, maybe some of that is that he did not have his opportunity to get sea legs at the agency before Covid began. But this is a do or die moment for the agency now.”

HHS secretary Alex Azar backed up his FDA chief. “Dr. Hahn has been a strong and effective leader of the Food and Drug Administration from his first day on the job and throughout the COVID-19 pandemic,” Azar said. “The agency has been instrumental in making PPE, therapeutics, diagnostics, and eventually vaccines available for the American public as quickly as possible.”

Surgeon General Jerome Adams also praised Hahn’s handling of the pandemic. “I think he was really pressured by the epidemic itself to try and decrease regulatory barriers,” Adams said. “He’s really done a good job of always saying ‘We’re doing this in an emergency situation and we’re also going to make sure we’re following the data, so we can quickly react to and respond to any problems.'”

The FDA chief’s reticence was clear at the April 28 meeting of the White House coronavirus task force where Birx laid into Marks about the nation’s vaccine strategy, according to the three people familiar with the event. Birx pressed Marks for clearer answers on which vaccines the government was working on or funding, and why it was not funding or studying others, said a fourth official familiar with the meeting.

But the FDA’s vaccine chief does not make those calls. Other scientists, including the chief of the Biomedical Advanced Research and Development Authority, dictate key funding decisions; BARDA’s former chief Rick Bright had been ousted just days before the tense task force meeting — a move Bright alleged was due to his resistance to hydroxychloroquine.

Neither Azar nor Hahn spoke up for Marks in the meeting, according to the three sources, who along with two others in that meeting said that Birx and Marks have since patched up the misunderstanding. The fourth official, and a fifth in the room, characterized the Birx and Marks exchange as brief. But the tense atmosphere — and silence from both Hahn and Azar — struck several attendees and people briefed afterward.

Birx referred questions on the matter to a task force spokesperson who declined to comment.

Asked about his departure from Warp Speed and the task force, Marks released a statement through the FDA press office. “I believe that the American public will be best served by my return full time to FDA, where I can continue to work collaboratively, with industry, government partners and other researchers and provide regulatory advice to expedite the development and availability of vaccines to combat COVID-19,” he said.

Marks’s decision to leave Warp Speed came just a week after President Trump named Moncef Slaoui — the former head of vaccines at GlaxoSmithKline and until recently, a member of Moderna Therapeutics’ board of directors — to lead the program.